Tags

Type your tag names separated by a space and hit enter

Treatment of Guillain-Barré syndrome and CIDP.
J Peripher Nerv Syst. 2005 Jun; 10(2):113-27.JP

Abstract

Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating poly-(radiculo)neuropathy (CIDP) are immune-mediated disorders with a variable duration of progression and a range in severity of weakness. Infections can trigger GBS and exacerbate CIDP. Anti-ganglioside antibodies are important, but there is debate on the role of genetic factors in the pathogenesis of these disorders. Randomized controlled trials (RCT) have shown that intravenous immunoglobulin (IVIg) and plasma exchange (PE) are effective in both GBS and CIDP. Most CIDP patients also improve after steroid therapy. Despite current treatment options, many patients have residual deficits or need to be treated for a long period of time. Therefore, new treatment trials are highly indicated. This review focuses on the current and possible new treatment options that could be guided by recent results from laboratory experiments.

Authors+Show Affiliations

Department of Neurology, Erasmus Medical Center, Dr. Molewaterplein 40, 3015 GD Rotterdam, the Netherlands. p.a.vandoorn@erasmusmc.nl

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

15958124

Citation

van Doorn, Pieter A.. "Treatment of Guillain-Barré Syndrome and CIDP." Journal of the Peripheral Nervous System : JPNS, vol. 10, no. 2, 2005, pp. 113-27.
van Doorn PA. Treatment of Guillain-Barré syndrome and CIDP. J Peripher Nerv Syst. 2005;10(2):113-27.
van Doorn, P. A. (2005). Treatment of Guillain-Barré syndrome and CIDP. Journal of the Peripheral Nervous System : JPNS, 10(2), 113-27.
van Doorn PA. Treatment of Guillain-Barré Syndrome and CIDP. J Peripher Nerv Syst. 2005;10(2):113-27. PubMed PMID: 15958124.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treatment of Guillain-Barré syndrome and CIDP. A1 - van Doorn,Pieter A, PY - 2005/6/17/pubmed PY - 2005/9/20/medline PY - 2005/6/17/entrez SP - 113 EP - 27 JF - Journal of the peripheral nervous system : JPNS JO - J. Peripher. Nerv. Syst. VL - 10 IS - 2 N2 - Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating poly-(radiculo)neuropathy (CIDP) are immune-mediated disorders with a variable duration of progression and a range in severity of weakness. Infections can trigger GBS and exacerbate CIDP. Anti-ganglioside antibodies are important, but there is debate on the role of genetic factors in the pathogenesis of these disorders. Randomized controlled trials (RCT) have shown that intravenous immunoglobulin (IVIg) and plasma exchange (PE) are effective in both GBS and CIDP. Most CIDP patients also improve after steroid therapy. Despite current treatment options, many patients have residual deficits or need to be treated for a long period of time. Therefore, new treatment trials are highly indicated. This review focuses on the current and possible new treatment options that could be guided by recent results from laboratory experiments. SN - 1085-9489 UR - https://www.unboundmedicine.com/medline/citation/15958124/Treatment_of_Guillain_Barré_syndrome_and_CIDP_ L2 - https://doi.org/10.1111/j.1085-9489.2005.0010203.x DB - PRIME DP - Unbound Medicine ER -